Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-Derived Stromal Cells in Dry AMD
NCT02024269Withdrawn
- Sponsor
- Bioheart, Inc.
- Start
- Dec 2013
- Primary completion
- Dec 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous adipose-derived stromal cells (Bioheart) in dry age-related macular degeneration, sponsored by Bioheart, Inc. Primary endpoints: Frequency and nature of adverse events at 6 months, Visual Field analysis (10-2) at 6 months and 1 more. Planned start Dec 2013; status: withdrawn.
02
Drugs
autologous adipose-derived stromal cells (Bioheart)
03
Conditions
dry age-related macular degeneration
Beyond the preview
Go deeper on NCT02024269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024269.